The association between cannabis use and anxiety disorders: results from a population-based representative sample. Feingold, D, et al.
European Neuropsychopharmacology. 2015 Dec. 29 (abstract).
Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. Bianconi, F, et al.
Psycological Medicine. 2015 Dec. 16 1-9 (abstract).
Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy. Zoja, C, et al.
Nephron. 2015 Dec. 9 (abstract).
Pharmaceutical CBD (cannabidiol) shows promise for children with severe epilepsy. Significant seizure reduction in studies using CBD in combination with AEDs. American Epilepsy Society.
Science Daily. 2015 Dec.7.
Head and neck cancer among marijuana users; a meta-analysis of matched case-control studies. de Carvalho, M F. et al.
Archives of oral Biology. 2015 Dec. 60(12): 1750-1755 (abstract).
Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with ∆9-tetrahydrocannabinol. Cluny, Nina L, et al.
PLOS One 2015 December 3.
Long-term data of efficacy, safety and tolerability in a real life setting of THC/CBD oromucosal spray-treated multiple sclerosis patients. Paolicelli, D, et al.
Journal of clinical Pharmacology. 2015 Nov. 26 (abstract).
Cannabis liberalization and adolescent cannabis use: a cross-national study in 38 countries. Shi, Yuyan, et al.
PLOS One 2015 November 25.
Controlled release tablet formulation containing natural 9 tetrahydrocannabinol. Punyamurthula, N S, et al.
Drug Development and Industrial Pharmacy. 2015 Nov. 20: 1-25 (abstract).
The effects of five day dosing with THCV in THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial. Englund, A, et al.
Journal of Psychopharmacology. 2015 Nov. 17 (abstract).
Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use. Sideli, L, et al.
Early Intervention in Psychiatry. 2015 Nov. 12 (abstract).
Pharmacological benefits of selective modulation of cannabinoid receptor type 2 (CB2) in experimental Alzheimer’s disease. Jayant, S, et al.
Pharmacological Biochemical Behavior. 2015 Nov. 11 (abstract).
Heavy cannabis users at elevated risk of stroke: evidence from a general population survey. Hemachandra, D, et al.
Australian and New Zealand Journal of Public Health. 2015 Nov. 11 (abstract).
Cannabinoid receptor type 1 agonist ACEA improves recovery and protects neurons in ischemic stroke in mice. Caltana, L, et al.
Journal of Neurochemistry. 2015 Nov. 135(3): 616-629 (abstract).
Perinatal asphyxia results in altered expression of the hippocampal acylethanolamide/ endocannabinoid signaling system associated to memory impairments in postweaned rats. Blanco, Eduardo, et al.
Frontiers in Neuroanatomy. 2015 November 3.
Metabolic syndrome among marijuana users in the United States: an analysis of national health and nutrition examination survey data. Vidot, D C, et al.
American Journal of Medicine. 2015 Nov. 5 (abstract).
Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice. Verty, A N A,
Plos One. 2015 November 20.
Substituting cannabis for prescription drugs, alcohol and other substance among medical cannabis patients: the impact of contextual factors. Lucas, Philippe, et al.
Drug and Alcohol Review. 2015 (abstract).
Cannabis species and cannabinoid concentration among sleep-disturbed medicinal cannabis users. Belendiuk, Katherine A, et al.
Addictive Behaviors. 2015 November 50: 176-181 (abstract).
Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Haney, M, et al.
Neuropsychopharmacology. 2015 Oct. 40(11): 2489-2498 (abstract).
A runner’s high depends on cannabinoid receptors in mice. Fuss, J, et al.
Proceedings of the National Academy of Sciences USA. 2015 112(42): 13105-8 (absract).
Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model arthritis. Hammell, D C, et al.
European Journal of Pain. 2015 Oct. 30 (absract).
Adult attention deficit hyperactivity symptoms and psychosis: epidemiological evidence from a population survey in England. Marwaha, S, et al.
Psychiatry Research. 2015 Sep.30, 229(1-2): 49-56 (abstract).
Relationship between cannabis and psychosis: reasons for use and associated clinical variables. Mané, A, et al.
Psychiatry Research. 2015 Sep.30, 229(1-2): 70-74 (abstract).
Cannabis for the management of pain: assessment of safety study (COMPASS). Ware, M A, et al.
Journal of Pain. 2015 Sep. 16 (see separate binder).
Association between marijuana use and adverse obstetrical and neonatal outcomes. Warshalk, C R, et al.
Journal of Perinatology. 2015 Sep.24 (abstract).
Cannabis. Grayson, Michelle.
Nature Supplement. 2015 September 24, 525 No. 750_supp ppS1-S18.
Actions of the dual FAAH/MAGL inhibitor JZL 195 in a murine neuropathic pain model. Adamson Barnes, N S, et al.
British Journal of Pharmacology. 2015 Sep. 23 (abstract).
Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys. Maguire, D R, et al.
Behavioural Pharmacology. 2015 Sep. 21 (abstract).
Neural correlates of cannabidiol and ∆9-tetrahydrocannabinol interactions in mice: implications for medical cannabis. Todd, S M, et al.
British journal of Pharmacology. 2015 Sep.17 (abstract).
Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Weiss, A, et al.
Drug and Alcohol Dependence. 2015 Sep.14 (abstract).
Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Lucas, P, et al.
Drug and Alcohol Review. 2015 Sep.14 (abstract).
Endocannabinoid modulation of predator stress-induced long-term anxiety in rats. Lim, J, et al.
Neuropsychopharmacology. 2015 Sep.11 (abstract).
Anadamide mediates cognitive judgement bias in rats. Kregiel, J, et al.
Neuropsychopharmacology. 2015 Sep. 9 (abstract).
The effect of medical marijuana laws on body weight. Sabia, Joseph J, et al.
Health Economics 2015 September 8.
Divergent marijuana trajectories among men: socioeconomic, relationship, and life satisfaction outcomes in the mid-30s. White, H R, et al.
Drug and Alcohol Dependence. 2015 Sep.5 (abstract).
Bone cell-autonomous contribution of type 2 cannabinoid receptor to breast cancer induced osteolysis. Sophocleous, Antonia, et al.
Journal of Biological Chemistry. 2015 Sep.4 290(36): 22049-60.
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Bisaga, A, et al.
Drug and Alcohol Dependence. 2015 Sep.1 154: 38-45 (abstract).
The genetic structure of marijuana and hemp. Sawler, Jason, et al.
PLOS One. 2015 Aug. 26.
Pro-inflammatory obesity in aged cannabinoid-2 receptor-deficient mice. Schmitz, K, et al.
International Journal of Obesity. 2015 Aug. 25 (abstract).
Shared predisposition in the association between cannabis use and subcortical brain structure. Pagliaccio, David et al.
JAMA Psychiatry 2015 August 26.
Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol. Ho, W S, et al.
British Journal of Pharmacology. 2015 Aug. 21 (abstract).
Sativex ® and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. Leocani, L, et al.
Journal of Neurology. 2015 Aug. 20 (abstract).
Association between use of marijuana and male reproductive hormones and semen quality: a study among 1,215 healthy young men. Gundersen, T D, et al.
American of Epidemiology. 2015, 182(6): 473-481.
Endocannabinoid regulation of amyloid-induced neuroinflammation. Vàzquez, C, et al.
Neurobiology of Aging. 2015 Aug.15 (abstract).
Cannabidiol, a cannabis sativa constituent, inhibits cocaine-induced seizures in mice: possible role of the mTOR pathway and reduction in glutamate release. Gobira, P H, et al.
Neurotoxicology. 2015 Aug.15 (abstract).
Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide prospective, register-based study. Hjorthøj, C, et al.
Lancet Psychiatry. 2015 Aug. 12 (abstract).
Neurocognitive and social cognitive predictors of cannabis use in first-episode psychosis. Arnold, C, et al.
Schizophrenia Research. Aug. 7 (abstract).
Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Bechtold, J, et al.
Psychology of Addictive Behaviors. 2015 Aug. 3 (abstract).
Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Mounsey, R B, et al.
Experimental Neurology. Aug. 2 273: 36-44 (abstract).
No additive effect of cannabis on cognition in schizophrenia. Power, B D, et al.
Schizophrenia Research. July 30 (abstract).
Brief report: cannabis smoking and diabetes mellitus: results from meta-analysis with eight independent replication samples. Alshaarawy, O, et al.
Epidemiology. 2015 July 26 (4): 597-600 (abstract).
Natural outcome of cannabis use disorder: a three-year longitudinal follow-up. Feingold, D, et al.
Addiction. 2015 July 25 (abstract).
Analysis of the anti-allodynic effects of combination of a synthetic cannabinoid and a selective noradrenaline re-uptake inhibitor in nerve injury-induced neuropathic mice. Gunduz, O, et al.
European Journal of Pain. 2015 July 24 (abstract).
Novel triazolopyrimidine-derived cannabinoid receptor 2 agonists as potential treatment for inflammatory kidney diseases. Nettekoven, M, et al.
ChemMedChem. 2015 July 21 (abstract).
Notes from the field: death following ingestion of an edible marijuana product – Colorado, March 2014. Hancock-Allen, Jessica B, et al.
Morbidity and Mortality Weekly Report. 2015 July 24 64(28): 771-772.
Time-dependent protection of CB2 receptor agonist in stroke. Yu, Seong-Jin, et al.
PLOS One. 2015 July 17 10(7).
Activation of CB2 receptor is required for the therapeutic of ABHD6 inhibition in experimental autoimmune encephalomyelitis. Wen, J, et al.
Neuropharmacology. 2015 July 17 99: 196-209 (abstract).
Cannabis allergy: what do we know anno 2015. Decuyper, I, et al.
Archivum Immunologiae et Therapiae Experimentalis. 2015 July 16 (abstract).
Enhanced vasorelaxation of endogenous anandamide on thoracic aorta in renal vascular hypertension rats. Guo, Z, et al.
Clinical and Experimental Pharmacology and Physiology. 2015 July 14 (abstract).
Cannabinoids and terpenes as chemotaxonomic markers in cannabis. Elzinga, S, et al.
Natural Products Chemistry & Research. 2015 3(4): 181.
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Bisaga, A, et al.
Drug and Alcohol Dependence. 2015 July 8 (abstract).
Nonsmoker exposure to secondhand cannabis smoke. III. Oral fluid and blood drug concentrations and corresponding subjective effects. Cone, E J, et al.
Journal of Analytical Toxicology. 2015 July 2 (abstract).
Cannabis use and reduced risk of insulin resistance analysis (ANRS CO13 HEPAVIH). Carrieri, Maria Patrizia et al.
Clinical Infectious Diseases. 2015 July 1 61.
Cannabis in cancer care. Abrams, Donald I, et al.
Clinical Pharmacology & Therapeutics. 2015 June 97(6): 575-586.
Medical marijuana for treatment of chronic pain and other medical and psychiatric problems. A clinical review.
Hill, Kevin P
JAMA. 2015 313 June 23/30 (24): 2474-2483.
Are cannabidiol and 9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. McPartland, John M, et al.
British Journal of Pharmacology. 2015 172: 737-753.
Cannabis sativa: the unconventional “weed” allergen. Ocampo, Thad L, et al.
Annals of Allergy, Asthma & Immunology. 2015 114: 187-92.
Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors. Shakoor, S, et al.
Psychiatry Research. 2015 June 30 227(2/3): 144-51 (abstract).
Cannabinoid dose and label accuracy in edible medical cannabis products. Vandrey, Ryan, et al.
JAMA. 2015 June 23/30 313(24): 2491-2493.
Medical marijuana. Is the cart before the horse. D’Souza, Deepak Cyril, et al.
JAMA. 2015 June 23/30 313(24): 2431-2432.
Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. Gilman, Jodi M, et al.
The Journal of Neuroscience. 2015 June 28 35(4): 1505-1512.
Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Stanley, C P, et al.
Cardiovascular Research. 2015 June 19 (abstract).
Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 1994: results from annual, repeated cross-sectional surveys. Hasin, Deborah S. et al.
The Lancet (psychiatry). 2015 June 16.
Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. Lynch, M E, et al.
Journal of Neuroimmune Pharmacology. 2015 June 10 (2): 293-301 (abstract).
Pharmacologic effects of cannabidiol on acute reperfused myocardial infarction in rabbits: evaluated with 3.OT cardiac magnetic resonance imaging and histopathology. Feng, Y, et al.
Journal of Cardiovascular Research. 2015 June 9 (abstract).
Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. van den Elsen, G A, et al.
Neurology. 2015 June 9 84(23): 2338-2346 (abstract).
Synergy between cannabidiol, cannabidiolic acid, and ∆9-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew). Rock, E M, et al.
Behavioral Neuroscience. 2015 June 129 (3): 368-70 (abstract).
Cannabinoids for medical use: a systematic review and meta-analysis. Whiting, Penny F, et al.
JAMA. 2015 313(24): 2456-2473.
Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Hartman, Rebecca L, et al.
Clinical Chemistry. 2015 61(6): 850-869.
Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. Presley, Chaela, et al.
Pharmacology, Research & Perspectives. 2015 3(4): 1-16.
Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been….. Baron, E P
Headache. 2015 May 25 (abstract).
Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Fu W, et al.
Neuroscience Letters. 2015 May 19 595:1-6 (abstract).
Cannabis smoking and diabetes mellitus: results from meta-analysis with eight independent replication samples. Alshaarawy, O, et al.
Epidemiology. 2015 May 14 (abstract).
CB1 receptors modulate affective behaviour induced by neuropathic pain. Rácz, I, et al.
Brain Research Bulletin. 2015 May 114: 42-48 (abstract).
Use of prescription pain medications among medical cannabis patients: comparison of pain levels, functioning, and patterns of alcohol and other drug use. Perron, Brian E, et al.
Journal of Studies on Alcohol and Drugs. 2015 May 76(3): 406-418.
The antitumor activity of plant-derived non-psychoactive cannabinoids. McAllister, Sean D, et al.
Journal of Neuroimmune Pharmacology. 2015 April.
Differential role of cannabinoids in the pathogenesis of skin cancer. Glodde, N, et al.
Life Sciences. 2015 April 25 (abstract).
A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Felilú, A, at al.
British Journal of Pharmacology. 2015 April 8 (abstract).
Current status and future of cannabis research. Russo, Ethan B, et al.
Clinical Researcher. 2015 April 58.
Introduction to the endocannabinoid system. Russo, Ethan
Phytex Website. 2015.
Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson’s disease patients in Colorado. Finseth, Taylor Andrew, et al.
Evidence Based Complementary and Alternative Medicine. 2015 article ID 874849.
Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder. Kvitland, Levi Roestad, et al.
BMC Psychiatry. 2015 15: 11.
Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation In Parkinson’s disease. Gòmez-Gálvez, Y, et al.
Progress in Neuropsychopharmacology & Biological Psychiatry. 2015 April 9 (abstract).
Efficacy of inhaled cannabis on painful diabetic neuropathy. Wallace, M S, et al.
Journal of Pain. 2015 April 2 (abstract).
Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Press, C A, et al. Epilepsy & Behavior. 2015 April 2 (abstract).
Medical marijuana for cancer. Kramer, Joan L.
CA A Cancer Journal for Clinicians. 2015 March/April 65(2): 109-122.
Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Bechtold, Jordan, et al.
Psychology of Addictive Behaviors. 2015 29(3): 552-563.
Overview of CBC Medicinal value of cannabinol (CBN)-Medical Marijuana Inc. 2015 Nov.11.
The disease-modifying effects of Savitex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to ∆(9)-tetrahydrocannabinol acting through CB1 receptors. Moreno-Martet, M, et al.
Multiple Sclerosis and Related Disorders. 2015 Nov. 4(6) 505-511 (abstract).
Overview of CBN. Medicinal value of cannabinol (CBN)-Medical Marijuana Inc. 2015 Oct.29.
No smoke, no fire: what the initial literature suggests regarding vapourized cannabis and respiratory risk. Loflin, Mallory, et al.
Canadian Journal of Respiratory Therapy. 2015 51(1): 7-9.
Cannabidiol, a major non-psychotrophic cannabis constituent enhances fracture healing and stimulates lysyl hydroxylase activity in osteoblasts. Kogan, N M, et al.
Journal of Bone and Mineral Research. 2015 March 19 (abstract)
Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Di Forti, Marta, et al.
The Lancet Psychiatry. 2015 March 2(3): 233-238.
Cannabis use in relation to obesity and insulin resistance in the Inuit population. Ngueta, Gerard et al.
Obesity. 2015 February 23(2).
Medical marijuana for digestive disorders: high time to prescribe? Gerich, Mark E, et al.
The American Journal of Gastroenterology. 2015 February 110: 208-214.
Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Ahmed, Amir I A, et al.
Psychopharmacology. 2015 232: 2587-2595.
Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. van der Meer, F J, et al.
Psychological Medicine. 2015 Feb. 5:1-12 (abstract).
Cannabis use in relation to obesity and insulin resistance in the Inuit population. Ngueta, G, et al.
Obesity. 2015 Feb. 23 (2): 290-295 (abstract).
Selective nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer. Morales, P, et al.
Journal of Medicinal Chemistry. 2015 Feb. 20 (abstract).
Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. Monteleone, A M, et al.
American Journal of Clinical Nutrition. 2015 Feb. 101(2): 262-269 (abstract).
Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol. Gallily, Ruth, et al.
Pharmacology & Pharmacy. 2015 Feb.10, 6: 75-85.
Association between cannabis use and the risk of bladder cancer: results from the California men’s health study. Thomas, A A, et al.
Urology. 2015 Feb. 85(2): 388-393 (abstract).
Synthetic and natural cannabinoids: the cardiovascular risk. Russo, Ethan B
The British Journal of Cardiology. 2015 22(1) January-March: 7-9.
Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Lachenmeier, Dirk W, et al.
Scientific Reports. 2015 Jan. 30.
Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Rahimi, A, et al.
Neuroscience. 2015 Jan.28: 290C: 279-287 (abstract).
Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. Weiland, Barbara, J, et al.
The Journal of Neuroscience. 2015 January 28 35(4): 1505-1512.
Proapoptotic effect of endocannabinoids in prostate cancer cells. Orellana-Serradell, O, et al.
Oncology Reports. 2015 Jan. 21.
Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption. Feng, R, et al.
Molecular Carcinogenesis. 2015 Jan. 16 (abstract).
The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Jetly, R, et al.
Psychoneuroendocrinology. 2015 Jan. 15, 51: 585-588 (abstract).
Two non-psychoactive cannabinoids reduce intra-cellular lipid levels and inhibit hepatosteatosis. Silvestri, C, et al.
Journal of Hepatology. 2015 Jan. 13 (abstract).
Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. de Campos, A C, et al.
Neuroscience. 2015 Jan. 13 (abstract).
Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: role of cyclooxcygenase-2 and novel J-series prostamides. Soliman, E, et al.
Molecular Carcinogenesis. 2015 Jan. 3 (abstract).
The conversation and transfer of cannabinoids from cannabis to smoke stream in cigarettes. Elzinga, Sytze, et al.
Natural Products and Chemistry Research. 2015 3 (1).